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Abstract
Germline mutations in the LKB1 gene (also known as STK11) cause the Peutz-Jeghers Syndrome, and somatic loss of LKB1
has emerged as causal event in a wide range of human malignancies, including melanoma, lung cancer, and cervical cancer.
The LKB1 protein is a serine-threonine kinase that phosphorylates AMP-activated protein kinase (AMPK) and other
downstream targets. Conditional knockout studies in mouse models have consistently shown that LKB1 loss promotes a
highly-metastatic phenotype in diverse tissues, and human studies have demonstrated a strong association between LKB1
inactivation and tumor recurrence. Furthermore, LKB1 deficiency confers sensitivity to distinct classes of anticancer drugs.
The ability to reliably identify LKB1-deficient tumors is thus likely to have important prognostic and predictive implications.
Previous research studies have employed polyclonal antibodies with limited success, and there is no widely-employed
immunohistochemical assay for LKB1. Here we report an assay based on a rabbit monoclonal antibody that can reliably
detect endogenous LKB1 protein (and its absence) in mouse and human formalin-fixed, paraffin-embedded tissues. LKB1
protein levels determined through this assay correlated strongly with AMPK phosphorylation both in mouse and human
tumors, and with mRNA levels in human tumors. Our studies fully validate this immunohistochemical assay for LKB1 in
paraffin-embedded formalin tissue sections. This assay should be broadly useful for research studies employing mouse
models and also for the development of human tissue-based assays for LKB1 in diverse clinical settings.
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Introduction
LKB1 (also known as STK11) has emerged as a major tumor
suppressor in diverse malignancies, particularly melanoma,
cervical cancer, and lung cancer [1–5]. The LKB1 gene encodes
a serine/threonine kinase that acts through a multitude of targets
to control diverse aspects of cell polarity, metabolism, and cell
growth [6,7]. Among these diverse substrates, the a catalytic
subunit of AMP-activated protein kinase (AMPK) is the best
established both in normal physiologic states and cancer. The
LKB1 protein, in association with the accessory proteins STRAD
and MO25, phosphorylates AMPKa at Thr172 in its activation
loop, leading to AMPK activation when AMPK is in the AMP-
bound state. AMPK directly phosphorylates TSC2 and raptor to
suppress signaling through mTOR pathway, and mTOR pathway
hyperactivity in the LKB1-deficient state is believed to account for
some, but not all of LKB1 tumor suppressor functions [8,9].
Considerable preclinical evidence exists that LKB1 deficiency
confers an unusually poor clinical outcome, sensitivity to distinct
classes of anticancer drugs, such as mTOR and SRC inhibitors,
and resistance to other drug classes, such as MEK inhibitors [10–
14]. It appears very likely that the ability to reliably identify LKB1-
deficient tumors would have ‘theranostic’ implications, and thus be
of clinical utility. However, no LKB1-based clinical assay has been
developed since the identification of LKB1 as a tumor suppressor
in 1998 [15]. In general, it has proven much more difficult to
develop useful clinical assays based on tumor suppressor inacti-
vation (e.g. deletion of RB or PTEN) than oncogene activation (e.g.
ERBB2 amplification, RAS/RAF activation). In large part this
relates to the much more expanded set of molecular alterations
that can inactivate a tumor suppressor (point mutation or
intragenic deletions throughout coding and cis-regulatory regions,
promoter hypermethylation, or diverse post-translational modifi-
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cations leading to protein instability) vs. the more limited set of
molecular alterations that define oncogene activation. This has
made it difficult to develop clinical assays with sufficient specificity
to reliably define states of tumor suppressor loss. For example,
even whole-gene sequencing has high false negative rates as it
misses several mechanisms that frequently inactivate tumor
suppressor proteins (e.g. degradation, promoter hypermethylation,
etc.).
Another practical consideration that further complicates such
efforts–particularly DNA-based assays– is that most tumors
contain abundant ‘‘contaminating’’ cells (e.g. lymphocytes,
tumor-associated stroma), which, in many cases, outnumber the
malignant cells harboring the actionable molecular alterations.
Specific gain-of-function/oncogenic mutations or gene amplifica-
tion events are readily detectable even in tumors with an abundant
background of such contaminating cells, whereas loss-of-function
mutations and deletions are more easily obscured.
In principle, the ability to reliably detect a tumor suppressor
protein in situ presents an attractive alternative, particularly as it
has the potential to capture most of the above mechanisms,
including post-translational mechanisms conferring protein insta-
bility. Several factors make LKB1 a particularly appealing
candidate for such efforts. First, intragenic deletions, insertions,
and splicing mutations (leading to frameshifts with alteration of
epitopes or complete absence of protein) are very common in
LKB1, as are larger intragenic deletions ranging from a single exon
up to 100 kb of genomic DNA [1]. Taken together, these types of
mutations occur in at least 50% of cases harboring LKB1
mutations [16]. Furthermore, some LKB1 point mutations result
in decreased protein stability [17]. However, identification of an
antibody with sufficient sensitivity and specificity suitable for in situ
detection is often difficult, and validation itself can be challenging
particularly if the tumor suppressor is ubiquitously expressed, as is
usually the case.
Although there are reports of LKB1 immunodetection in
specific research settings, no assay has been extensively validated,
proven robust, or widely adopted; e.g. across multiple cancer types
[11,18–22]. Here we describe a rabbit LKB1 monoclonal antibody
capable of detecting the endogenous protein in clinical material
(i.e. paraffin-embedded, formalin-fixed human tissue) with excel-
lent performance characteristics. Furthermore, this method is also
applicable to studies of LKB1 loss in murine preclinical model
systems. Additional studies demonstrated that assays based on this
approach can serve as the basis of clinical tests to identify tumors
characterized by LKB1 loss.
Materials and Methods
Ethics Statements
Mouse experiments were conducted with the approval of the
UT Southwestern Institutional Animal Care and Use Committee
and the Dana Farber Institutional Animal Care and Use
Figure 1. Validation of LKB1 rabbit monoclonal antibody D60C5 for immunohistochemistry in human and mouse paraffin-
embedded, formalin-fixed samples. A, Human cervical cancer cell lines. HeLa/Lkb1 = HeLa cells following transduction of lentivirus harboring a
human LKB1 cDNA inducible expression construct. Relative expression levels of Lkb1 protein are indicated in parentheses. B, Mouse tissues
(endometrium and lung) from animals harboring floxed alleles of Lkb1 following Cre-mediated recombination with Sprr2f-Cre (endometrium) or nasal-
instillation of Adeno-Cre virus (lung). Distinct Lkb1-null clones are indicated by dashed lines (endometrium) or arrows (lung). Bars = 10 mm for each
panel. Asterisks in the lung panels show invasive cancer cells subjacent to the dysplastic epithelium; these invasive cancer cells are also clearly Lkb1-
null. C, Percent of Lkb1-null cells in Sprr2f-Cre; Lkb1L/L female mice by immunohistochemistry at 3, 6, 12, and 20 weeks of age. Error bar = S.E.M. D,
Normal patterns of LKB1 protein in human lung and oviduct highlighting localization to the apical surface of ciliated cells (arrows). Note: in the
oviduct, ciliated epithelial cells (arrows) are interspersed among nonciliated cells. Bars = 10 mm in both panels.
doi:10.1371/journal.pone.0073449.g001
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Committee. For the human biomarker studies, study subjects were
accrued as part of a research protocol (requiring written informed
consent) approved by the University of North Carolina Office of
Human Research Ethics (see also below).
Mouse colonies, alleles, and Adeno-Cre virus instillation
Mice were housed in a pathogen-free animal facility in
microisolator cages and fed ad libitum on standard chow under
standard lighting conditions; experiments were conducted with the
approval of Institutional Animal Care and Use Committees.
Sprr2f-Cre; Lkb1L/L endometrial Lkb1-knockout mice were bred
and generated as previously described [10]. Breeding of LSL-
KrasG12V; Lkb1L/L mice and Adeno-Cre nasal instillation to effect
bronchial Cre-mediated recombination was conducted as previ-
ously described [2]. Mice were treated with Adeno-Cre at 8 weeks
of age and euthanized 10 weeks later.
Cell lines and preparation of cell blocks for
immunohistochemistry
Human cervical carcinoma cell lines HeLa [cat# CCL-2] and
CaSki [cat# CRL-1550] were purchased from the ATCC and
grown on plastic tissue culture plates in low glucose DMEM
(Gibco) +10% fetal bovine serum. Tet-On-LKB1-Hela cells (see
below) were grown in low glucose DMEM (Gibco) +10%
tetracycline-free fetal bovine serum (Clontech) + puromycin
(1 mg/ml) (Clontech) and G418 (400 mg/ml) (Gibco) media. To
overexpress human LKB1 in these cells a Lentivirus-Tet-On-
LKB1 plasmid was generated by cloning an LKB1 cDNA into the
BamHI-XbaI sites of the pLVX-Tight-Puro vector (Clontech).
The pLVX-Tight-Puro-LKB1 and the pLVX-Tet-On Advanced
vectors (Clontech) were co-transfected (1:1 ratio) with the Lenti-X
HT Packaging Mix kit (Clontech) into HEC293T cells. 24 hours
later, the transfection medium was replaced with fresh medium
and incubated at 37uC for 48 hours to produce lentivirus particles.
HeLa cells were infected with Lentivirus-Tet-On-LKB1 particles
for 24 hours with polybrene (4ug/ml) (Sigma-Aldrich H9268)
followed by replacement of the culture medium with fresh
complete culture medium. To induce LKB1 expression, doxycy-
cline (500 ng/ml) (Sigma-Aldrich) was added to the culture
medium and incubated at 37uC for 48 hours.
Confluent cells were harvested with a cell scraper without
trypsin/EDTA treatment and briefly spun down in a 15 ml
conical tube. The cell pellet was resuspended in 10% buffered
formalin and incubated at RT for 1 hour. The cells were washed
twice in PBS, resuspended in an equal volume of 2% low melting
temperature agarose (Cambrex), and cast in the wells of 96-well
plates. To simulate routine clinical pathology laboratory process-
ing of diagnostic tissue samples, the solidified plugs were subjected
to overnight fixation and paraffin-embedding, and cut into 5 m
sections.
Figure 2. Testing of another a-LKB1 monoclonal antibody (Ley 37D/G6). Tissue sections are from the uterus of a 6-week old Sprr2f-Cre;
Lkb1L/L female mouse. Rabbit monoclonal D60C5 readily distinguishes LKB1 positive from negative cells as shown previously. In contrast, the mouse
monoclonal antibody Ley 37D/G6 shows a homogeneous pattern throughout the endometrial epithelium (serial step section) and fails to distinguish
between LKB1 positive and negative cells. Size bars = 100 m for each panel.
doi:10.1371/journal.pone.0073449.g002
Figure 3. Validation of rabbit monoclonal antibody D60C5 by Western blotting. Positions of molecular weight standards (kilodaltons) are
shown to the left of each blot. A, HeLa cells harboring Tet-On construct inducible with doxycycline. B, Comprehensive uterine cancer cell line panel
(endometrial and cervical). Note: C4I harbors biallelic mutations of LKB1: a chromosomal deletion plus a point mutation that does not affect protein
levels [1]. CaSki, C33, and ME180 do not harbor LKB1 mutations [1]. Endo was derived from normal endocervical epithelium immortalized with HPV
E6/E7 [27].
doi:10.1371/journal.pone.0073449.g003
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Tissue processing, LKB1/pAMPKa (Thr172)
immunohistochemistry, and scoring of protein levels
Tissues were fixed in 10% formalin for 24 hours at 4o, washed
twice in PBS, then processed and embedded in paraffin. 5 m
sections were cut onto SuperFrost Plus slides (Fisher Scientific),
deparaffinized in xylene, and hydrated in a graded ethanol series.
Antigen retrieval was performed by gentle boiling in 10 mM
sodium citrate pH 6.0 followed by cooling at room temperature for
20 minutes. Endogenous peroxidase activity was quenched with
3% hydrogen peroxide in ddH20 for 30 minutes, followed by
blocking in 1% BSA (in PBS) for 15 minutes. The primary
antibodies used for immunohistochemistry were a-phospho-
AMPKa (Thr172) (1:50 dilution) (rabbit monoclonal 40H9, Cell
Signaling Technologies catalog #2535) and a concentrated
preparation of a-LKB1 rabbit monoclonal D60C5 (Cell Signaling
Technologies #3047BF [2.2 mg/ml in PBS]), used at dilutions of
1:10000 (for mouse tissues) and 1:500 (for human tissues) of ).
Note: this is available as a custom reagent from the manufacturer.
The ‘‘off-the-shelf’’ manufacturer’s preparation (catalog #3047) is
provided at a concentration optimized for Western blotting that is
too low for immunohistochemistry of human tissue sections; i.e.
this reagent (24 mg/ml, Cell Signaling Technologies #3047)
would require 1:6 dilution. We recommend that each laboratory
optimize antibody dilutions for every tissue. The other commercial
antibodies tested on tissue sections of our paraffin-embedded,
formalin fixed human cell line panel and Sprr2f-Cre; Lkb1L/L
mosaic uterus were: Proteintech rabbit polyclonal (catalog
#10746); Cell Signaling rabbit monoclonal 27D10 (cat#3050s);
EMD Millipore rabbit polyclonal (catalog# ST1092); EMD
Millipore mouse monoclonal 5C10 (catalog #05-832); Abcam
mouse monoclonal Ley37D/G6 (catalog #ab15095). These
antibodies were tested using the above immunodetection protocol
at titers ranging from 1:100 to 1:10000 with no evidence of specific
staining at any titer (see results for representative example-
Ley37D/G6).
ImmPRESS (Vector laboratories) was employed as a secondary
detection system, and applied for 30 minutes. For detection, DAB
(3,39-diaminobenzidine) (Dakocytomation) was used as a substrate-
chromogen. The processed slides were counterstained with
hematoxylin, air-dried, and mounted in Permount (Fisher
Scientific).
Lung cancer tissue cores in a triplicate set of tissue-microarrays
(TMAs) were used to collect immunohistochemistry data. Based
on the range of staining intensities observed on the TMAs,
investigators scored LKB1 protein expression on each slide with a
four category scale. The total signal within the cell was scored with
no distinction between subcellular localization patterns, since no
Figure 4. Scoring schema for LKB1 and pAMPKa (Thr172) expression in human lung cancer specimens. Tissues were paraffin-embedded
and fixed in formalin. Only staining in the malignant epithelial cells was scored. A, LKB1 immunohistochemistry and representative cases illustrating
histologic scores. B, pAMPKa (Thr172) immunohistochemistry and representative cases illustrating histologic scores. The dynamic range was
somewhat lower for pAMPKa (Thr172) vs. LKB1 but a wide range of staining intensities was also observed. Bar = 10 mm in all panels; all panels are at
same magnification.
doi:10.1371/journal.pone.0073449.g004
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Median Age at Diagnosis 65.8 years
doi:10.1371/journal.pone.0073449.t001
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obvious variation in subcellular expression patterns (e.g. in nuclear
vs. cytoplasmic localization) were noted. Only cancer cells were
scored; tumor stroma was not evaluated. Stromal staining was
evident in most cores, serving as a useful positive control and
reference point for staining intensity. The maximum score of the
triplicate set was selected as a single summary value for the entire
set. Patients were included in each analysis for which complete
clinical, genetic, and immunochemistry data was available.
Patient Clinical and Genomics Data
Study subjects were accrued as part of a tissue banking protocol
under Institutional Review Board approved protocols 90-0573 and
07-0120 at UNC. All patients were treated for non-small cell lung
cancer at UNC hospitals and clinical data was obtained by
retrospective chart review. All genomic data (gene expression
arrays, copy number array, and sequencing) from the current
study has been previously reported and are publically available
and are described in detail elsewhere [23–25]. Gene expression
data is from the Agilent 44 K platform to measure gene
expression, copy number data was obtained using the Affymetrix
Mapping 250 K Sty2 SNP Array and the Affymetrix Genome-
Wide Human SNP 6.0 Array. Sequencing of LKB1 has been
described in the prior report [24].
Statistical methods
Ordered logistic regression was employed for analysis in cases of
ordered categorical outcomes. For group comparisons the
Wilcoxon rank sum statistic was used. For differences in
categorical outcomes Fisher’s exact test was used. All analyses
and figures were performed using the R 2.15.2 software
environment (21).
Results and Discussion
To screen for a suitable antibody, we analyzed a panel of three
human cancer cell lines: HeLa (harbors biallelic LKB1 deletions,
expresses no protein), CaSki (LKB1 wild-type, expresses normal
levels of protein), and HeLa transduced with an LKB1 cDNA
(expresses abnormally high levels of protein). The cells were grown
under routine culture conditions, and subjected to formalin-
fixation and paraffin-embedding to simulate clinical conditions.
Five commercial (see methods) and several non-commercial a-
LKB1 antibodies were comprehensively tested, including two
rabbit monoclonals and two mouse monoclonals. Results for only
Figure 5. Validation of LKB1 antibody in situ assay in human lung tumor specimens. A, LKB1 protein expression vs. gene expression scores.
Researchers used the Agilent 44 K platform to measure gene expression. A positive relationship was observed (p,0.01). B, Box plots showing
comparison of gene expression scores in cases with confirmed LKB1 loss-of-function mutations vs. cases with no mutations. C, Protein expression by
mutation status providing visual comparison of cases with mutation vs. no mutation. The x-axis shows the percentage of cases per LKB1 score (i.e.
each side adds up to 1). The unsymmetrical shape indicates differences between the groups.
doi:10.1371/journal.pone.0073449.g005
Figure 6. Correlation between LKB1 and pAMPKa (Thr172)
scores. Heat map shows associations between LKB1 and pAMPKa
(Thr172) protein expression scores. Kendall’s tau provides a summary of
the correlation (tk= 0.49, p,0.001).
doi:10.1371/journal.pone.0073449.g006
Table 2. Coding mutations and LKB1 scores.
Mutation(s) LKB1 scores
exon 1: p.E70X 0 0 0
exon 2: p.Q123R 1 1 1
exon 4: p.Q170X 0 0 0
exon 4: splicing 0 0 0
exon 5: p.G242W 0 0 0
exon 5: splicing 1 0 0
exon 1: p.I88I exon 4: p.D194Y 0 0 0
doi:10.1371/journal.pone.0073449.t002
LKB1 Detection in Tissues
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one antibody (rabbit monoclonal clone D60C5) were consistent
with faithful binding to and detection of the LKB1 protein by
standard indirect immunohistochemistry (Fig. 1A). These analyses
are detailed below.
As previously described, by 12 weeks of age, Lkb1 loss drives
endometrial cancer in mice, while combined Lkb1 loss/Kras
activation drives the formation of lung cancer. The endometrial-
specific Sprr2f-Cre driver results in Cre-mediated recombination in
50–60% of endometrial epithelial cells by 6 weeks of age,
providing an ideal mosaic system for in vivo biomarker validation
[10]. In wild-type murine endometria, all epithelial cells stained
strongly and uniformly for Lkb1 (Fig. 1B). Stromal cells also
expressed the protein, albeit at lower levels. In sharp contrast,
however, Sprr2f-Cre; Lkb1L/L mice at 6 weeks of age exhibited a
strikingly mosaic pattern of Lkb1 expression, consistent with clonal
Cre-driven loss of Lkb1 and specific Lkb1 immunodetection. Of
note, under optimized conditions, background staining in the
Lkb1-null epithelial clones was minimal. Concordantly, pAMPKa
(Thr172) immunohistochemistry of serial sections provided com-
pelling evidence that 1) the pAMPKa (Thr172) antibody was also
reliable for in situ analyses and 2) AMPKa is indeed an Lkb1 target
hypophosphorylated in vivo following Lkb1 loss (Fig. 1B). At 12 and
20 weeks, 100% of Sprr2f-Cre; Lkb1L/L endometrial epithelial cells
were Lkb1-null, consistent with a selective growth advantage of the
Lkb1-null cells (Fig. 1C).
Similar results were obtained in an Lkb1/Kras adeno-Cre nasal
instillation model of lung carcinogenesis [2]. Whereas control
lungs showed uniform Lkb1 expression, mice treated with adeno-
Cre showed mosaic patterns of Lkb1 expression in the bronchial
epithelium that is subject to adenovirus infection. Furthermore,
while some Lkb1-deficient clones appeared morphologically
normal, most showed clear evidence of dysplasia and hyperplasia
(leftmost vs. two right lung panels, Fig. 1B), consistent with a causal
association between Lkb1 loss and dysplasia/tumor progression.
Invasive tumor cells in this model were always Lkb1-negative
(asterisks, Fig. 1B). Interestingly, in ciliated cells (lung bronchial
epithelium, oviductal epithelium), the LKB1 protein was promi-
nently expressed in the apical surface (i.e. in the cilia), consistent
with LKB1’s known roles in the establishment and maintenance of
epithelial polarity [26]. This asymmetric staining also serves as a
convenient positive control whereby these readily-available normal
human tissues can be used to confirm that immunostaining was
performed correctly (Fig. 1D). We conclude that this LKB1
antibody reliably detects the endogenous protein in diverse human
and mouse tissues, making it ideal for biomarker studies employing
both human cancer specimens (see below) and mouse cancer
models. For comparative purposes, a representative monoclonal
antibody (Ley37D/G6) for which we could not demonstrate
specific immunostaining in either the human cell line panel or in
Lkb1-mosaic mouse tissues is shown (Fig. 2). We note that our
inability to demonstrate specific immunostaining under our
experimental conditions does not invalidate the potential utility
of an antibody for specific experimental conditions, tissues, etc.,
that we did not test.
Western blotting was performed to further validate and test the
specificity of this antibody. In lysates obtained from unmodified
HeLa cells or HeLa cells harboring a Tet-on-LKB1 construct
prior to induction, no protein species were detected. Following
induction with doxycycline, however, a specific band correspond-
ing to LKB1 was detected (Fig. 3A). To further test the
performance of the antibody, it was also tested against lysates
derived from a comprehensive panel of uterine cell lines, both
endometrial and cervical (n = 22). No LKB1 protein was detected
in most cervical cancer cell lines (6/11), consistent with prior
reports that a high percentage of cervical cancers are characterized
by biallelic LKB1 inactivation. However, LKB1 was expressed in
some cervical cancer cell lines, as previously reported [1]. LKB1
protein was expressed in all endometrial cancer cell lines (n = 10),
although there was considerable variation in its expression levels
(Fig. 3B). Note that all of these images were minimally cropped
and no other species were detected. These results demonstrate that
the antibody is essentially monospecific with respect to LKB1
when tested against a diverse panel of human cell lines by Western
blotting. We conclude that this antibody displays exceptional
specificity for LKB1.
To test the utility of the antibody in clinical lung cancer
specimens, immunohistochemistry was performed on a triplicate
set of tissue-microarrays (TMAs) containing lung cancer tissue
cores. Patient demographics were representative of a typical
clinical population in the USA (Table 1). Interestingly, a very
broad range of LKB1 staining intensities were observed, showing
that LKB1 levels are highly variable in lung cancers, and hence
that LKB1 could serve as a discriminating biomarker. Based on
the range of staining intensities observed, a scoring scale (0–3) was
devised, where 0 =no appreciable staining; 1 = very low staining
but above background; 2 = strong staining; and 3= very strong
staining. Each member of the triplicate set was scored, and the
maximum score was selected as a single summary value for the
entire set. In general, staining intensities in each tissue core were
uniform across the tumor cells (Fig. 4A). To further validate LKB1
as a potential biomarker, TMA slides were also stained for
pAMPKa (Thr172) and a similar scoring scheme was devised
(Fig. 4B). A total of 123 cases were scored for both markers
(Table 1).
We then assessed relationships between LKB1 protein expres-
sion in this TMA of human lung cancers and other genomic
measures performed on RNA/DNA prepared from fresh samples
of the same tumors. First, the LKB1 protein expression scores were
compared with RNA expression levels as determined by micro-
array profiling. Ordered logistic regression analysis demonstrated
a positive relationship between protein scores and gene expression
(n= 122; p = 0.002), observed as a positive upward slope on the
plot shown in Fig. 5A. This is further evidence that the LKB1
antibody can faithfully detect the protein in clinical samples.
Consistent with this interpretation, tumors with confirmed loss-of-
function mutations showed lower average gene expression scores
(p = 0.059, Wilcoxon rank sum test) (Fig. 5B). Likewise for protein
expression scores, statistical and visual comparison of the two
groups (mutation predicted to alter protein vs. no mutation,
Table 2) showed lower protein expression in the mutation group;
the plot is asymmetrical, and cases with mutations were skewed
towards ‘‘0’’ scores (Fig. 5C; Fisher’s Exact Test p = 0.04). Thus,
although post-translational mechanisms may also contribute to
LKB1 downregulation in tumors, statistically-significant relation-
ships were observed between LKB1 protein scores and expression
at the RNA level as well as mutational status. However, the
number of cases with LKB1 mutations was too small to assess
relationships between types of mutations (e.g. premature stop vs.
single amino acid substitutions) and LKB1 protein scores; such a
determination will require larger studies. Next, we assessed the
correlation between LKB1 and pAMPKa (Thr172) scores. A heat
map was used for a graphical representation of the association of
LKB1 and pAMPKa (Thr172) scores (Fig. 6). There was a
significant association among cases which were scored for both
markers (n = 122; Kendall’s tau = 0.54, p,0.001), strongly arguing
that both LKB1 and pAMPKa (Thr172) are interrelated
biomarkers useful for interrogating LKB1 status in human clinical
samples.
LKB1 Detection in Tissues
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In conclusion, we have shown through human cell lines and
mouse in vivo models that endogenous levels of the LKB1 protein
can be readily detected in multiple cell types in tissue sections.
Furthermore, this assay can discriminate between different levels
of LKB1 expression in human cancers. This assay, which employs
a monoclonal antibody, should thus prove highly reproducible and
easily adopted by diverse research or clinical laboratories for
diverse investigations of the potential of LKB1 as a predictor of
clinical outcomes in diverse human malignancies.
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